July 20, 2026

Oral Nicotinamide May Offer Cost-Effective Prevention of Keratinocyte Carcinoma

Oral nicotinamide may provide a cost-effective strategy for preventing keratinocyte carcinoma (KC) in persons at high risk, according to a study published in JAMA Dermatology. Led by David Perez, BA, ...

The ASCO Post

April 24, 2026

Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin

Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, in 2025, about 154,270 individ...

The ASCO Post

April 08, 2026

AAD Issues Pediatric Atopic Dermatitis Guidelines

Two companion guidelines provide 41 evidence-based recommendations on treatment and prevention, along with 29 statements on comorbidity associations in patients under 18

MDSpire News

April 06, 2026

Fullerene Cream vs Trolamine Cream in Reducing Acute Radiation Dermatitis From Radiation Therapy for Head and Neck Cancer

In a single-center Chinese phase II trial reported in the Journal of Clinical Oncology, Liu et al found that fullerene cream was better than trolamine cream in reducing risk for acute radiation dermat...

The ASCO Post

March 30, 2026

Therapeutic Advances in Metastatic Melanoma: TILs, ImmTACs, and Targeted Therapies

Jadpro

March 24, 2026

Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma

A response-adapted approach to treatment decision-making for patients with resectable cutaneous squamous cell carcinoma demonstrated that with the use of neoadjuvant pembrolizumab, many patients could...

The ASCO Post

March 24, 2026

Adjuvant Pembrolizumab Plus Belzutifan May Provide a New Standard of Care for Patients With Renal Cell Carcinoma at Increased Risk of Recurrence

Based on results from the phase III KEYNOTE-564 study,1 adjuvant pembrolizumab is currently a standard of care for patients with clear cell renal cell carcinoma who have an increased risk of recurrenc...

The ASCO Post

February 24, 2026

Adjuvant Coformulated Vibostolimab Plus Pembrolizumab in High-Risk Stage IIB to IV Melanoma

In an interim analysis of a phase III trial (KEYVIBE-010) reported in The Lancet Oncology, Dummer et al found that adjuvant therapy with a coformulation of the anti-TIGIT antibody vibostolimab with pe...

The ASCO Post

February 19, 2026

Stage II Melanoma: Adjuvant Pembrolizumab and Risk of New Skin Cancers

Is prior adjuvant pembrolizumab associated with the risk of developing subsequent cutaneous malignant neoplasms in patients with high-risk stage II melanoma? A secondary analysis of the phase III KEYN...

The ASCO Post

February 18, 2026

Building Better Oral Suspensions for Pediatric & Real-World Use

Greg Thomas, Kiel Laboratories’ Vice President of R&D, discusses oral suspensions, excipients, and patient-centered formulation

The Medicine Maker